Evidence map›Paper›PMID 35340213›Full record

ArticleOxidative medicine and cellular longevity2022

Sanguinarine-Chelerythrine Fraction of

Maciej Danielewski, Sylwia Zielińska, Agnieszka Matuszewska, Wojciech Słupski, Maciej Włodarczyk, Izabela Jęśkowiak, Benita Wiatrak, Krzysztof Kowalski, Anna Jezierska-Domaradzka, Piotr Ziółkowski and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Sanguinarine-Chelerythrine fromPharmaceutics · 2025
    Article
  4. Article
  5. Recent Advances in Alkaloids fromMolecules (Basel, Switzerland) · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Preclinical safety evaluation ofFrontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Maciej DanielewskiDepartment of Pharmacology, Wroclaw Medical University, J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland.
Sylwia ZielińskaDepartment of Pharmaceutical Biotechnology, Wroclaw Medical University, Borowska 211, 50-556 Wrocław, Poland.ORCID https://orcid.org/0000-0003-0090-5486
Agnieszka MatuszewskaDepartment of Pharmacology, Wroclaw Medical University, J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland.ORCID https://orcid.org/0000-0003-1082-0793
Wojciech SłupskiDepartment of Pharmacology, Wroclaw Medical University, J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland.ORCID https://orcid.org/0000-0002-0833-7711
Maciej WłodarczykDepartment of Pharmacognosy and Herbal Medicines, Wroclaw Medical University, Borowska 211A, 50-556 Wrocław, Poland.ORCID https://orcid.org/0000-0002-2671-5747
Izabela JęśkowiakDepartment of Pharmacology, Wroclaw Medical University, J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland.ORCID https://orcid.org/0000-0002-8829-4482
Benita WiatrakDepartment of Pharmacology, Wroclaw Medical University, J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland.ORCID https://orcid.org/0000-0002-1404-2274
Krzysztof KowalskiDepartment of Pharmacology, Wroclaw Medical University, J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland.
Anna Jezierska-DomaradzkaDepartment of Pharmaceutical Biotechnology, Wroclaw Medical University, Borowska 211, 50-556 Wrocław, Poland.ORCID https://orcid.org/0000-0001-7834-846X
Piotr ZiółkowskiDepartment of Pathology, Wroclaw Medical University, K. Marcinkowskiego 1, 50-368 Wrocław, Poland.ORCID https://orcid.org/0000-0003-3036-2611
Adam SzelągDepartment of Pharmacology, Wroclaw Medical University, J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland.ORCID https://orcid.org/0000-0001-8104-5267
Beata NowakDepartment of Pharmacology, Wroclaw Medical University, J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland.ORCID https://orcid.org/0000-0003-0014-6344
Wroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory diseases are a common therapeutic problem and nonsteroidal anti-inflammatory drugs are not deprived of side effects, of which ulcerogenic activity is one of the most frequent. The aim of the study was to evaluate the anti-inflammatory activity of the sanguinarine-chelerythrine (SC) fraction of

Indexed as

Coptis chinensisEdemaAnimalsAnti-Inflammatory AgentsBenzophenanthridinesCarrageenanIsoquinolinesMaleRatsAnti-Inflammatory AgentsBenzophenanthridinesCarrageenanchelerythrineIsoquinolinessanguinarine

Identifiers

PMID35340213
PMCPMC8942652
OpenAlexW4220848864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.